產(chǎn)品目錄

規(guī)格	10 mM * 1 mL in DMSO5mg 10mg 25mg 50mg 100mg
CAS	56990-57-9
別名	N/A
化學(xué)名	(7E)-8-oxo-7-[(6-sulfonaphthalen-2-yl)hydrazinylidene]quinoline-5-sulfonic acid
分子式	C19H13N3O7S2
分子量	459.45
溶解度	≥ 45.9mg/mL in DMSO, ≥ 16.6 mg/mL in H2O with ultrasonic
儲(chǔ)存條件	Store at 4°C
General tips	For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping Condition	Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request

產(chǎn)品描述：

IC50: NSC-87877 potently inhibited Shp2 with an IC50 of 0.318 ± 0.049 μM. NSC-87877 seemed to have no selectivity between human Shp2 and Shp1 (IC50 0.355 ± 0.073μM). In addition, NSC-87877 showed approximately 5-, 24-, 206-, 266-, and 475-fold selectivity for Shp2 over PTP1B (IC50 1.691 ± 0.407μM), HePTP (IC50 7.745 ± 1.561μM), DEP1 (IC50 65.617± 4.120μM), CD45 (IC50 84.473 ± 16.185μM), and LAR (IC50 150.930 ± 9.077μM), respectively [1].

Shp2, a nonreceptor protein tyrosine phosphatase (PTP) encoded by the PTPN11 gene, is involved in the growth factorinduced activation of mitogen-activated protein kinases Erk1 and Erk2. Moreover, gain-of-function Shp2 mutations have been found in Noonan syndrome and childhood leukemias. Therefore, Shp2 PTP inhibitors are required for the evaluation of Shp2 as a therapeutic target. NSC87877, a novel SHP-2 inhibitor, has been observed dose-dependent cytotoxicity in leukemic cell lines.

In vitro: Molecular modeling and site-directed mutagenesis studies suggested that NSC-87877 binds to the catalytic cleft of Shp2 PTP. It is noteworthy that NSC-87877 inhibited epidermal growth factor (EGF)-induced activation of Shp2 PTP, Ras, and Erk1/2 in cell cultures but did not block EGF-induced Gab1 tyrosine phosphorylation or Gab1-Shp2 association. Furthermore, NSC-87877 inhibited Erk1/2 activation by a Gab1-Shp2 chimera but did not affect the Shp2-independent Erk1/2 activation by phorbol 12-myristate 13-acetate. These results identified NSC-87877 as the first PTP inhibitor capable of inhibiting Shp2 PTP in cell cultures without a detectable off-target effect [1].

In vivo: An mice in-vivo study aimed to investigate the effects of S NSC-87877 on inflammatory pain and its underlying mechanisms. In this study, immediately after behavioral tests, sinistral spinal dorsal horn was collected for immunoblotting analysis of the expression of NMDA receptors. Results showed that NSC-87877 alleviated CFA-induced mechanical allodynia, which had no effects on the nociceptive responses in naive mice. Moreover, NSC-87877 specifically abolished the increase in the synaptic expression of NMDA receptor NR2B subunits in inflamed mice. These findings indicated that NSC-87877 could ameliorate inflammatory pain by inhibiting the synaptic accumulation of NR2B in spinal dorsal horn [2].

Clinical trial: NSC-87877 is currently in the preclinical development and no clinical trial is ongoing.

特別提醒：

1. 本產(chǎn)品僅供科研使用。請(qǐng)勿用于醫(yī)藥、臨床診斷或治療，食品及化妝品等用途。請(qǐng)勿存放于普通住宅區(qū)。

2. 為了您的安全和健康，請(qǐng)穿好實(shí)驗(yàn)服并佩戴一次性手套和口罩操作。

原創(chuàng)作者：上海莼試生物技術(shù)有限公司

在線咨詢

留言注意事項(xiàng)：

1.遵守中華人民共和國(guó)有關(guān)法律、法規(guī)，尊重網(wǎng)上道德，承擔(dān)一切因您的行為而直接或間接引起的法律責(zé)任。

2.請(qǐng)您真實(shí)的反映產(chǎn)品的情況,不要捏造、誣蔑、造謠。如對(duì)產(chǎn)品有任何疑問,也可以留言咨詢。

3.未經(jīng)本站同意，任何人不得利用本留言簿發(fā)布個(gè)人或團(tuán)體的具有廣告性質(zhì)的信息或類似言論。

您感興趣的產(chǎn)品*
您的單位*
聯(lián)系人*
聯(lián)系電話*
詳細(xì)地址*
常用郵箱*
請(qǐng)輸入您對(duì)我們的意見或建議*
驗(yàn)證碼*